1811. Impact of a one-time oritavancin infusion on hospital length of stay for uncomplicated skin and soft tissue infections

BACKGROUND: Oritavancin is a lipoglycopeptide antibiotic approved in the United States for the treatment of adults with skin and soft tissue infections (SSTIs). Given the extended half-life of this agent, a one-time intravenous (IV) infusion is adequate to treat SSTIs. This single IV dose provides a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bremmer, Derek N, Alvarez, Gabriela, Buchanan, Carley, Carr, Dustin R, Shively, Nathan R, Moffa, Matthew A, Trienski, Tamara, Walsh, Thomas L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677577/
http://dx.doi.org/10.1093/ofid/ofad500.1640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677577/
http://dx.doi.org/10.1093/ofid/ofad500.1640

Ejemplares similares